Literature DB >> 23286317

Expression of 11β-hydroxysteroid dehydrogenase type 1 in the human hypothalamus.

P H Bisschop1, M J H J Dekker, W Osterthun, J Kwakkel, J J Anink, A Boelen, U A Unmehopa, J W Koper, S W J Lamberts, P M Stewart, D F Swaab, E Fliers.   

Abstract

The hypothalamus is a major target for glucocorticoids and a key structure for hypothalamic-pituitary-adrenal (HPA) axis setpoint regulation. The enzyme 11β hydroxysteroid dehydrogenase type 1 (11βHSD1) modulates glucocorticoid signalling in various tissues at the prereceptor level by converting biologically inactive cortisone to its active form cortisol. The present study aimed to assess 11βHSD1 expression in the human hypothalamus. We studied 11βHSD1 expression in five frozen and four formalin-fixed, paraffin-embedded human hypothalami (obtained from the Netherlands Brain Bank) by the polymerase chain reaction and immunocytochemistry, respectively. 11βHSD1 mRNA was expressed in the area of the suprachiasmatic nucleus, which is the biological clock of the brain, in the supraoptic nucleus and paraventricular nucleus (PVN), and in the infundibular nucleus, which is the human homologue of the rodent arcuate nucleus. 11βHSD1 was detected by immunocytochemistry in the same nuclei. In the PVN, neuronal 11βHSD1 immunoreactivity colocalised with corticotrophin-releasing hormone (CRH), arginine vasopressin and oxytocin, as shown by dual fluorescence staining. Our data demonstrate that 11βHSD1 is widely expressed in the human hypothalamus. Its colocalisation with CRH in the PVN suggests a role in modulation of glucocorticoid feedback of the HPA axis, whereas the expression of 11βHSD1 in additional and functionally diverse hypothalamic nuclei points to a role for the enzyme in the regulation of metabolism, appetite and circadian rhythms.
© 2013 British Society for Neuroendocrinology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23286317     DOI: 10.1111/jne.12017

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  11 in total

Review 1.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

Review 2.  Changing glucocorticoid action: 11β-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation.

Authors:  Karen E Chapman; Agnes E Coutinho; Zhenguang Zhang; Tiina Kipari; John S Savill; Jonathan R Seckl
Journal:  J Steroid Biochem Mol Biol       Date:  2013-02-19       Impact factor: 4.292

3.  Mutations in IRS4 are associated with central hypothyroidism.

Authors:  Charlotte A Heinen; Emmely M de Vries; Mariëlle Alders; Hennie Bikker; Nitash Zwaveling-Soonawala; Erica L T van den Akker; Boudewijn Bakker; Gera Hoorweg-Nijman; Ferdinand Roelfsema; Raoul C Hennekam; Anita Boelen; A S Paul van Trotsenburg; Eric Fliers
Journal:  J Med Genet       Date:  2018-07-30       Impact factor: 6.318

Review 4.  Cortisol on Circadian Rhythm and Its Effect on Cardiovascular System.

Authors:  Nor Amira Syahira Mohd Azmi; Norsham Juliana; Sahar Azmani; Nadia Mohd Effendy; Izuddin Fahmy Abu; Nur Islami Mohd Fahmi Teng; Srijit Das
Journal:  Int J Environ Res Public Health       Date:  2021-01-14       Impact factor: 3.390

Review 5.  Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe.

Authors:  Claire S Martin; Mark S Cooper; Rowan S Hardy
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

Review 6.  The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids.

Authors:  Henrik Oster; Etienne Challet; Volker Ott; Emanuela Arvat; E Ronald de Kloet; Derk-Jan Dijk; Stafford Lightman; Alexandros Vgontzas; Eve Van Cauter
Journal:  Endocr Rev       Date:  2017-02-01       Impact factor: 19.871

7.  Regulation of 11β-hydroxysteroid dehydrogenase type 1 and 7α-hydroxylase CYP7B1 during social stress.

Authors:  Martin Vodička; Peter Ergang; Anna Mikulecká; Lenka Řeháková; Petra Klusoňová; Jakub Makal; Matúš Soták; Jana Musílková; Petr Zach; Jiří Pácha
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

8.  11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.

Authors:  Erika Harno; Elizabeth C Cottrell; Alice Yu; Joanne DeSchoolmeester; Pablo Morentin Gutierrez; Mark Denn; John G Swales; Fred W Goldberg; Mohammad Bohlooly-Y; Harriet Andersén; Martin J Wild; Andrew V Turnbull; Brendan Leighton; Anne White
Journal:  Endocrinology       Date:  2013-10-29       Impact factor: 4.736

9.  A specific mutation in TBL1XR1 causes Pierpont syndrome.

Authors:  Charlotte A Heinen; Aldo Jongejan; Peter J Watson; Bert Redeker; Anita Boelen; Olga Boudzovitch-Surovtseva; Francesca Forzano; Roel Hordijk; Richard Kelley; Ann H Olney; Mary Ella Pierpont; G Bradley Schaefer; Fiona Stewart; A S Paul van Trotsenburg; Eric Fliers; John W R Schwabe; Raoul C Hennekam
Journal:  J Med Genet       Date:  2016-01-14       Impact factor: 6.318

10.  Role of 11β-HSD type 1 in abnormal HPA axis activity during immune-mediated arthritis.

Authors:  Janko Sattler; Jinwen Tu; Shihani Stoner; Jingbao Li; Frank Buttgereit; Markus J Seibel; Hong Zhou; Mark S Cooper
Journal:  Endocr Connect       Date:  2018-01-31       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.